Back to search

University of Ioannina

Εκτίμηση του κόστους και της αποτελεσματικότητας από τη θεραπεία της ρευματοειδούς αρθρίτιδας με βιολογικούς παράγοντες

Abstract

dc:description

Rheumatoid arthritis is a chronic disease, estimated to suffer from this approximately 40,00050,000 thousand Greeks (approximately 0.5% of the population). Usually affects the small joints symmetrically causing pain and limiting mobility. When the disease is not controlled, the quality of life of patients severely degraded. Objective: To compare the relative effectiveness of biological therapies approved for rheumatoid arthritis (RA) on health-related quality of life in patients diagnosed with RA. Also, a cost-effectiveness analysis was used to investigate of there is a therapy that optimizes the overall social benefit. Methods: Patients with RA treated with biologic agents were included in the study. Abatacept and anti-Tumor necrosis factor (TNF) agents: adalimumab, etanercept, golimumab and certolizumab were used in patients’ therapy. The patients were assessed using the Medical Outcomes Study Health Assessment Questionnaire-Disability Index (HAQ-DI), EuroQuol-5D (EQ-5D), Global Visual Analogue scale (VAS), to assess the state of health patient, Global Visual Analogue scale (VAS), to assess the level of pain. Also, the direct costs were recorded to apply a cost-effectiveness analysis. The period was 12 months. Results: One hundred fifty patients were studied. HAQ-DI improved after 12-months follow up. In the same way, the analysis showed a significant improvement for the EQ-5D, DAS-28, VAS-General and VAS-Pain after 12 months. Comparing the five treatment options the analysis didn’t reveale significant differences among them for HAQ-DI, EQ-5D, DAS-28, VAS-General and VAS-Pain. Finally, the results indicate that the biological agents are equivalent in terms of cost-effectiveness. The average direct cost per patient ranges from 8148 to 13214 EUR while the average indirect costs range from 4120 to 4980 EUR. Conclusion: This study revealed similar effectiveness of abatacept, adalimumab, etanercept, certolizumab and golimumab in health-related quality of life measures among RA patients while as much as the cost, there was an increase in costs in abatacept without exists a significant increase in efficiency.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Bozios, Panagiotis
  • Μπόζιος, Παναγιώτης

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/44903

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bozios, Panagiotis; Μπόζιος, Παναγιώτης. Εκτίμηση του κόστους και της αποτελεσματικότητας από τη θεραπεία της ρευματοειδούς αρθρίτιδας με βιολογικούς παράγοντες. University of Ioannina, 2017. http://hdl.handle.net/10442/hedi/44903